Axonics Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics or view top-rated stocks.

7 analysts have issued twelve-month price targets for Axonics' shares. Their AXNX stock forecasts range from $62.00 to $79.00. On average, they expect Axonics' stock price to reach $70.17 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts' price targets for Axonics or view top-rated stocks among Wall Street analysts.

Axonics' stock was trading at $56.00 at the start of the year. Since then, AXNX stock has increased by 4.6% and is now trading at $58.57.
View the best growth stocks for 2022 here.

Axonics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Axonics.

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Thursday, May, 5th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.19. The firm earned $48.42 million during the quarter, compared to analysts' expectations of $45.37 million. Axonics had a negative trailing twelve-month return on equity of 16.54% and a negative net margin of 41.28%. The business's quarterly revenue was up 40.9% on a year-over-year basis. During the same period last year, the company posted ($0.46) EPS.
View Axonics' earnings history.

Axonics updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $238.00 million-$238.00 million, compared to the consensus revenue estimate of $234.08 million.

12 employees have rated Axonics CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

Some companies that are related to Axonics include NovoCure (NVCR), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Inari Medical (NARI), iRhythm Technologies (IRTC), Haemonetics (HAE), Merit Medical Systems (MMSI), NuVasive (NUVA), Glaukos (GKOS) and Beauty Health (SKIN).
View all of AXNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

(AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Axonics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.37%), Vanguard Group Inc. (5.98%), Bellevue Group AG (4.35%), RTW Investments LP (3.70%), Loomis Sayles & Co. L P (3.27%) and Lord Abbett & CO. LLC (2.64%). Company insiders that own Axonics stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, Jane E Kiernan, John Woock, Karen Noblett, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics.

AXNX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RTW Investments LP, Goldman Sachs Group Inc., Vanguard Group Inc., Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, and BlackRock Inc.. Company insiders that have sold Axonics company stock in the last two years include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics or view top insider-selling stocks.

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Next Century Growth Investors LLC, Champlain Investment Partners LLC, Bellevue Group AG, Loomis Sayles & Co. L P, Granite Investment Partners LLC, First Light Asset Management LLC, and Lisanti Capital Growth LLC.
View insider buying and selling activity for Axonics or or view top insider-buying stocks.

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXNX stock can currently be purchased for approximately $58.57.

Axonics (NASDAQ:AXNX) has a market capitalization of $2.76 billion and generates $180.29 million in revenue each year. The company earns $-80.07 million in net income (profit) each year or ($1.81) on an earnings per share basis.

Axonics employs 517 workers across the globe.

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for Axonics is www.axonics.com. The company can be reached via phone at (866) 722-5738, via email at [email protected], or via fax at 949-396-6321.